Photo from wikipedia
Key Points Bendamustine with rituximab was the preferred frontline regimen, while BTK inhibitors were preferred in second or later lines of therapy. The presence of chromosome 17p deletion or TP53… Click to show full abstract
Key Points Bendamustine with rituximab was the preferred frontline regimen, while BTK inhibitors were preferred in second or later lines of therapy. The presence of chromosome 17p deletion or TP53 mutation did not shorten the overall survival in BTK inhibitor– treated patients.
Keywords:
world treatment;
patterns outcomes;
outcomes mantle;
treatment patterns;
real world;
evaluating real
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!